Advertisement

Impfungen und Krebserkrankungen

  • Angelika WagnerEmail author
  • Ursula Wiedermann-Schmidt
Chapter

Zusammenfassung

Personen mit Krebserkrankungen sind aufgrund ihrer Erkrankung und Therapie anfälliger für Infektionskrankheiten. Prophylaktische Impfungen können impf-präventable Infektionserkrankungen verhindern bzw. deren Verlauf abmildern. Die Wirksamkeit von Impfungen kann jedoch bei KrebspatientInnen wegen der veränderten Immunitätslage und besonders durch die Therapie eingeschränkt sein. Deswegen sollte der Impfstatus möglichst vor Therapieeinleitung überprüft und vervollständigt werden. Gleichzeitig sollen auch enge Bezugspersonen in die Impfberatung miteinbezogen werden, um die PatientInnen indirekt zu schützen. In Abhängigkeit, ob Lebend- oder Totimpfstoffe indiziert sind, gilt es gewisse Intervalle vor und nach Therapie einzuhalten. Während einer Chemotherapie sind Lebendimpfstoffe gänzlich kontraindiziert, Totimpfstoffe hingegen können verabreicht werden, wenngleich mit einer geringeren Wirksamkeit zu rechnen ist.

Literatur

  1. Abbas A, Lichtman A, Pillai S (2018) Cellular and molecular immunology, 9. Aufl. Saunders, CanadaGoogle Scholar
  2. Almirall J, Serra-Prat M, Bolibar I, Balasso V (2017) Risk factors for community-acquired pneumonia in adults: a systematic review of observational studies respiration. International review of thoracic diseases 94:299–311PubMedCrossRefGoogle Scholar
  3. Alwarawrah Y, Kiernan K, MacIver NJ (2018) Changes in nutritional status impact immune cell metabolism and function. Front Immunol 9:1055PubMedPubMedCentralCrossRefGoogle Scholar
  4. Ariza-Heredia EJ, Chemaly RF (2015) Practical review of immunizations in adult patients with cancer. Hum Vaccin Immunother 11:2606–2614PubMedPubMedCentralCrossRefGoogle Scholar
  5. Backhaus E, Berg S, Andersson R et al (2016) Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors. BMC Infect Dis 16:367PubMedPubMedCentralCrossRefGoogle Scholar
  6. Baden LR, Swaminathan S, Angarone M et al (2016) Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 14(7):882–913PubMedCrossRefGoogle Scholar
  7. BAG u. EKIF (2014a) Empfehlungen zur Impfung von Empfängerinnen und Empfängern von Blut-Stammzellen. Bull BAG 2012; 21:363–370 (angepasst Januar 2014)Google Scholar
  8. BAG u. EKIF (2014b) Pneumokokkenimpfung: Empfehlungen zur Verhinderung von invasiven Pneumokokkenerkrankungen bei Risikogruppen. Bull BAG 8:129–141.Google Scholar
  9. BAG u. EKIF (2018) Schweizerischer Impfplan 2018. www.bag.admin.ch/impfplanGoogle Scholar
  10. Bastola R, Noh G, Keum T et al (2017) Vaccine adjuvants: smart components to boost the immune system. Arch Pharm Res 40:1238–1248PubMedCrossRefGoogle Scholar
  11. Bektas O, Karadeniz C, Oguz A, Berberoglu S, Yilmaz N, Citak C (2007) Assessment of the immune response to trivalent split influenza vaccine in children with solid tumors. Pediatr Blood Cancer 49:914–917PubMedCrossRefGoogle Scholar
  12. Berghmans T, Sculier JP, Klastersky J (2003) A prospective study of infections in lung cancer patients admitted to the hospital. Chest 124:114–120PubMedCrossRefGoogle Scholar
  13. Berglund A, Willen L, Grodeberg L, Skattum L, Hagberg H, Pauksens K (2014) The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab. Acta Oncol 53:1212–1220PubMedCrossRefGoogle Scholar
  14. Berkowitz EM, Moyle G, Stellbrink HJ et al (2015) Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis 211:1279–1287PubMedCrossRefGoogle Scholar
  15. Bitterman R, Eliakim-Raz N et al (2018) Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev 2:CD008983.  https://doi.org/10.1002/14651858.CD008983.pub3 CrossRefPubMedGoogle Scholar
  16. Briere EC, Rubin L, Moro PL et al (2014) Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 63(RR-01):1–14PubMedGoogle Scholar
  17. CDC (2018) Seasonal Influenza Vaccine Effectiveness, 2004–2018. https://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm. Zugegriffen am 16.10.2018
  18. Chiou WY, Hung SK, Lai CL et al (2015) Effect of 23-valent pneumococcal polysaccharide vaccine inoculated during anti-cancer treatment period in elderly lung cancer patients on community-acquired pneumonia hospitalization: a nationwide population-based cohort study. Medicine 94(26):e1022PubMedPubMedCentralCrossRefGoogle Scholar
  19. Chou JF, Kernan NA, Prockop S et al (2011) Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant 17(11):1708–1713PubMedPubMedCentralCrossRefGoogle Scholar
  20. Conrad A, Alcazer V, Valour F, Ader F, Lyon HSG (2018) Vaccination post-allogeneic hematopoietic stem cell transplantation: what is feasible? Expert Rev Vaccines 17:299–309PubMedCrossRefGoogle Scholar
  21. Cordonnier C, Labopin M, Chesnel V et al (2010) Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine 28:2730–2734PubMedCrossRefGoogle Scholar
  22. Cordonnier C, Ljungman P, Juergens C et al (2015) Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged >/=2 years: an open-label study. Clin Infect Dis 61(3):313–323PubMedPubMedCentralCrossRefGoogle Scholar
  23. Cunningham AL, Lal H, Kovac M et al (2016) Efficacy of the Herpes Zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 375(11):1019–1032PubMedCrossRefGoogle Scholar
  24. Derosa L, Hellmann MD, Spaziano M et al (2018) Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol 29(6):1437–1444PubMedPubMedCentralCrossRefGoogle Scholar
  25. Dooling K-L, Guo A, Patel M et al (2018) Recommendations of the advisory committee on immunization practices for use of Herpes Zoster Vaccines. MMWR 67:103–108PubMedGoogle Scholar
  26. Dreyer S, Hemarajata P, Hogeling M, Henderson GP (2017) Pediatric vaccine-strain herpes zoster: a case series. Pediatr Dermatol 34:665–667PubMedCrossRefGoogle Scholar
  27. ECDC (2018) Monthly measles and rubella monitoring report, August 2018. https://ecdc.europa.eu/sites/portal/files/documents/measles-and-rubella-monitoring-report-Sep-2018.pdf. Zugegriffen am 16.10.2018
  28. Empfehlung zur jährlichen Influenza-Impfung („Grippeimpfung“) (2017). https://www.bmgf.gv.at/cms/home/attachments/3/0/3/CH1100/CMS1507802512474/influenza_stellungnahme.pdf. Zugegriffen am 16.10.2018
  29. Esposito S, Cecinati V, Brescia L, Principi N (2010) Vaccinations in children with cancer. Vaccine 28:3278–3284PubMedCrossRefGoogle Scholar
  30. Goossen GM, Kremer LC, van de Wetering MD (2013) Influenza vaccination in children being treated with chemotherapy for cancer. Cochrane Database Syst Rev:CD006484Google Scholar
  31. Greenberg RN, Gurtman A, Frenck RW et al (2014) Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60–64 years of age. Vaccine 32:2364–2374PubMedCrossRefGoogle Scholar
  32. Hansson E, Forbes HJ, Langan SM, Smeeth L, Bhaskaran K (2017) Herpes zoster risk after 21 specific cancers: population-based case-control study. Br J Cancer 116:1643–1651PubMedPubMedCentralCrossRefGoogle Scholar
  33. Harris AE, Styczynski J, Bodge M, Mohty M, Savani BN, Ljungman P (2015) Pretransplant vaccinations in allogeneic stem cell transplantation donors and recipients: an often-missed opportunity for immunoprotection? Bone Marrow Transplant 50:899–903PubMedCrossRefGoogle Scholar
  34. Hilgendorf I, Freund M, Jilg W et al (2011) Vaccination of allogeneic haematopoietic stem cell transplant recipients: report from the international consensus conference on clinical practice in chronic GVHD. Vaccine 29:2825–2833PubMedCrossRefGoogle Scholar
  35. Jaffe D, Papadopoulos EB, Young JW et al (2006) Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood 108:2470–2475PubMedPubMedCentralCrossRefGoogle Scholar
  36. José R, Mohammed A, Goldring J, Chambers R, Brwon J, Agarwal B (2015) Cancer patients with community-acquired pneumonia treated in intensive care have poorer outcomes associated with increased illness severity and septic shock at admission to intensive care: a retrospective cohort study. Pneumonia 6:77–82PubMedPubMedCentralCrossRefGoogle Scholar
  37. Kawamura K, Yamazaki R, Akahoshi Y et al (2015) Evaluation of the immune status against measles, mumps, and rubella in adult allogeneic hematopoietic stem cell transplantation recipients. Hematology 20:77–82PubMedCrossRefGoogle Scholar
  38. Kotecha RS, Wadia DU, Jacoby P et al (2016) Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer. Cancer Med 5:285–293PubMedCrossRefGoogle Scholar
  39. Kumar D, Chen MH, Welsh B et al (2007) A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin Infect Dis 45:1576–1582PubMedCrossRefGoogle Scholar
  40. Kumar D, Humar A, Plevneshi A et al (2008) Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance. Bone Marrow Transplant 41:743–747PubMedCrossRefGoogle Scholar
  41. Kunisaki KM, Janoff EN (2009) Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 9:493–504PubMedPubMedCentralCrossRefGoogle Scholar
  42. Kwon HJ, Lee JW, Chung NG, Cho B, Kim HK, Kang JH (2012) Assessment of serologic immunity to diphtheria-tetanus-pertussis after treatment of Korean pediatric hematology and oncology patients. J Korean Med Sci 27:78–83PubMedCrossRefGoogle Scholar
  43. Lal H, Cunningham AL, Godeaux O et al (2015) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372:2087–2096PubMedCrossRefGoogle Scholar
  44. Laubli H, Balmelli C, Kaufmann L et al (2018) Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. J Immunother Cancer 6:40PubMedPubMedCentralCrossRefGoogle Scholar
  45. Lee HY, Hsieh YC, Liu CC et al (2018) Invasive pneumococcal pneumonia caused by 13-valent pneumococcal conjugate vaccine types in children with different schedules. J Microbiol Immunol Infect 51(2):199–206PubMedCrossRefGoogle Scholar
  46. Ljungman P, Nahi H, Linde A (2005) Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol 130:96–98PubMedCrossRefGoogle Scholar
  47. Ljungman P, Cordonnier C, Einsele H et al (2009) Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant 44(8):521–526PubMedCrossRefGoogle Scholar
  48. Lopez A, Mariette X, Bachelez H et al (2017) Vaccination recommendations for the adult immunosuppressed patient: a systematic review and comprehensive field synopsis. J Autoimmun 80:10–27PubMedCrossRefGoogle Scholar
  49. Mahler MB, Taur Y, Jean R, Kernan NA, Prockop SE, Small TN (2012) Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18:145–149PubMedCrossRefGoogle Scholar
  50. Mikati T, Taur Y, Seo SK, Shah MK (2013) International travel patterns and travel risks of patients diagnosed with cancer. J Travel Med 20:71–77PubMedCrossRefGoogle Scholar
  51. Nakashima K, Aoshima M, Ohfuji S et al (2017) Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy. Hum Vaccin Immunother 13:543–550PubMedCrossRefGoogle Scholar
  52. Natori Y, Humar A, Lipton J et al (2017) A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 52:1016–1021PubMedCrossRefGoogle Scholar
  53. Niehues T, Bogdan C, Hecht J, Mertens T, Wiese-Posselt M, Zepp F (2017) Impfen bei Immundefizienz. Bundesgesundheitsblatt:674–684Google Scholar
  54. Nilsson A, De Milito A, Engström P et al (2002) Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. Pediatrics 109(6):e91PubMedCrossRefGoogle Scholar
  55. Rieger CT, Liss B, Mellinghoff S et al (2018) Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Oncol 29:1354–1365PubMedPubMedCentralCrossRefGoogle Scholar
  56. RKI (2016) Wissenschaftliche Begründung für die Aktualisierung der Empfehlungen zur Indikationsimpfung gegen Pneumokokken für Risikogruppen. Epidemiologisches Bulletin 37/2016. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2016/Ausgaben/37_16.pdf?__blob=publicationFile. Zugegriffen am 16.10.2018
  57. RKI (2018) Empfehlungen der Ständigen Impfkommission (STIKO) beim Robert Koch-Institut – 2018/2019. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2018/Ausgaben/34_18.pdf?__blob=publicationFile. Zugegriffen am 16.10.2018
  58. Sanada Y, Yakushijin K, Nomura T et al (2016) A prospective study on the efficacy of two-dose influenza vaccinations in cancer patients receiving chemotherapy. Jpn J Clin Oncol 46:448–452PubMedCrossRefGoogle Scholar
  59. Sarmati L, Andreoni M, Antonelli G et al (2017) Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. Clin Microbiol Infect 23:935–940PubMedCrossRefGoogle Scholar
  60. Schuster MG, Cleveland AA, Dubberke ER et al (2017) Infections in hematopoietic cell transplant recipients: results from the organ transplant infection project, a multicenter, prospective, cohort study. Open Forum Infecti Dis 4:ofx050Google Scholar
  61. Seggewiss R, Einsele H (2010) Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 115:3861–3868PubMedCrossRefGoogle Scholar
  62. Shanis D, Anandi P, Grant C et al (2018) Risks factors and timing of genital human papillomavirus (HPV) infection in female stem cell transplant survivors: a longitudinal study. Bone Marrow Transplant 53:78–83PubMedCrossRefGoogle Scholar
  63. Shetty AK, Winter MA (2012) Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation. Ochsner J 12:228–243PubMedPubMedCentralGoogle Scholar
  64. Shigayeva A, Rudnick W, Green K et al (2016) Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs. Clin Infect Dis 62:139–147PubMedCrossRefGoogle Scholar
  65. Steele RW (2012) Managing infection in cancer patients and other immunocompromised children. Ochsner J 12:202–210PubMedPubMedCentralGoogle Scholar
  66. Suzuki M, Dhoubhadel BG, Ishifuji T et al (2017) Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis 17:313–321PubMedCrossRefGoogle Scholar
  67. Svensson T, Kättsträm M, Hammarlund Y et al (2018) Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group. Vaccine 36:3701–3707PubMedCrossRefGoogle Scholar
  68. Tomblyn M, Chiller T, Einsele H et al (2009) Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 15:1143–1238PubMedPubMedCentralCrossRefGoogle Scholar
  69. Torres A, Peetermans WE, Viegi G, Blasi F (2013) Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 68:1057–1065PubMedPubMedCentralCrossRefGoogle Scholar
  70. Tsigrelis C, Ljungman P (2016) Vaccinations in patients with hematological malignancies. Blood Rev 30:139–147PubMedCrossRefGoogle Scholar
  71. van Veen KE, Brouwer MC, van der Ende A, van de Beek D (2016) Bacterial meningitis in hematopoietic stem cell transplant recipients: a population-based prospective study. Bone Marrow Transplant 51:1490–1495PubMedCrossRefGoogle Scholar
  72. Voican CS, Mir O, Loulergue P et al (2016) Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Ann Oncol 27:2172–2184PubMedCrossRefGoogle Scholar
  73. Vollaard A, Schreuder I, Slok-Raijmakers L, Opstelten W, Rimmelzwaan G, Gelderblom H (2017) Influenza vaccination in adult patients with solid tumours treated with chemotherapy. Eur J Cancer 76:134–143PubMedCrossRefGoogle Scholar
  74. Ward EM, Flowers CR, Gansler T, Omer SB, Bednarczyk RA (2017) The importance of immunization in cancer prevention, treatment, and survivorship. CA Cancer J Clin 67:398–410PubMedCrossRefGoogle Scholar
  75. Wiedermann U, Sitte HH, Burgmann H et al (2016) Guidelines for vaccination of immunocompromised individuals. Wien Klin Wochenschr 128(Suppl 4):337–376PubMedCrossRefGoogle Scholar
  76. Wiedermann-Schmidt U, Rendi-Wagner P, Aigner G, et al (2012) Impfungen für Mitarbeiter des Gesundheitswesens. https://www.meduniwien.ac.at/hp/fileadmin/tropenmedizin/DokumenteChristina/Impfempfehlungen_fuer_Gesundheitspersonal_s.pdf. Zugegriffen am 16.10.2018
  77. Wiedermann-Schmidt U, Kollaritsch H, Bachinger G, et al (2013) Reaktionen und Nebenwirkungen nach Impfungen. https://www.bmgf.gv.at/cms/home/attachments/1/5/5/CH1100/CMS1386342769315/impfungen-reaktionen_nebenwirkungen.pdf. Zugegriffen am 16.10.2018
  78. Winston DJ, Mullane KM, Cornely OA et al (2018) Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet 391:2116–2127PubMedCrossRefGoogle Scholar
  79. Wumkes ML, van der Velden AM, Los M et al (2013) Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours. Vaccine 31:6177–6184PubMedCrossRefGoogle Scholar
  80. Yri OE, Torfoss D, Hungnes O et al (2011) Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood 118:6769–6771PubMedCrossRefGoogle Scholar
  81. Zengin E, Sarper N (2009) Humoral immunity to diphtheria, tetanus, measles, and hemophilus influenzae type b in children with acute lymphoblastic leukemia and response to re-vaccination. Pediatr Blood Cancer 53:967–972PubMedCrossRefGoogle Scholar
  82. Zignol M, Peracchi M, Tridello G et al (2004) Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer 101:635–641PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2020

Authors and Affiliations

  1. 1.Institut für Spezifische Prophylaxe und TropenmedizinMedizinische Universität WienWienÖsterreich

Personalised recommendations